Less than 10% of individuals that would benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it releases its first advice on the drugs.
Given over a billion individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key barriers to universal access to the jabs that can assist patients in reducing considerable body mass, says the organization.
Skinny Jab Shortage
Even under the current best projected case, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice calls on governments and firms to increase access, by measures such as licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Work
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so users reduce food intake.
Individuals usually start to lose weight within a few weeks of starting on the regular doses.
Evidence indicates people may regain a significant portion after a year of halting the medication, because their normal food cravings resume.
To be carrying excess weight elevates your chance for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity impacts people in every country and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
